Intellia Therapeutics (NTLA) Set to Announce Quarterly Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) is scheduled to release its earnings data before the market opens on Thursday, November 7th. Analysts expect Intellia Therapeutics to post earnings of ($1.37) per share for the quarter.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The company had revenue of $7.00 million during the quarter, compared to the consensus estimate of $19.68 million. During the same period in the previous year, the company earned ($1.40) EPS. Intellia Therapeutics’s revenue for the quarter was down 48.5% compared to the same quarter last year. On average, analysts expect Intellia Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Intellia Therapeutics Stock Up 0.1 %

Shares of Intellia Therapeutics stock traded up $0.02 on Tuesday, hitting $15.16. The stock had a trading volume of 1,139,681 shares, compared to its average volume of 1,636,843. The stock’s 50-day simple moving average is $19.70 and its two-hundred day simple moving average is $22.38. Intellia Therapeutics has a one year low of $13.95 and a one year high of $34.87. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of -2.78 and a beta of 1.81.

Insider Buying and Selling

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of Intellia Therapeutics stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the transaction, the chief accounting officer now owns 47,012 shares in the company, valued at approximately $893,698.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.20% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on NTLA shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $54.00 price objective on shares of Intellia Therapeutics in a research note on Thursday, September 19th. The Goldman Sachs Group lowered their price target on Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Evercore ISI upgraded Intellia Therapeutics to a “strong-buy” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. decreased their target price on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 12th. Finally, Citigroup cut their price target on shares of Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Intellia Therapeutics has an average rating of “Moderate Buy” and an average target price of $59.13.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.